Ignite Creation Date:
2024-05-06 @ 11:47 AM
Last Modification Date:
2024-10-26 @ 12:49 PM
Study NCT ID:
NCT03593187
Status:
COMPLETED
Last Update Posted:
2022-11-07
First Post:
2018-06-15
Brief Title:
A Study Evaluating the Safety of Cal-1 LVsh5C46 Drug Product in HIV-1 Infected Patient With High Risk Lymphoma
Sponsor:
Assistance Publique - Hôpitaux de Paris
Organization:
Assistance Publique - Hôpitaux de Paris
Study Overview
Official Title:
A Phase III Study of the Safety of CD34 Haematopoietic StemProgenitor Cells and CD4 T Lymphocytes Transduced With LVsh5C46 a Dual Anti-HIV Gene Transfer Construct in HIV-1 Infected Patients With High-risk Lymphoma
Status:
COMPLETED
Status Verified Date:
2022-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
GENHIV
Brief Summary:
The purpose of this study is to evaluate the safety and the feasibility and the success of engraftment of the introduction of Cal-1 gene-transduced haematopoietic cell populations Ttn and HSPCtn in patients with HIV-1-related high-risk lymphoma
Detailed Description:
not provided
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2015-004453-41 | EUDRACT_NUMBER | None | None |